scr888 hacker app:scr888,hacker,app,锘,leading,bi:锘?p>As a leading biopharmaceutical company in Hong Kong, Kingsray Biotech () is particularly concerned by investors in the recent period. In particular, after the US stock market Gilead's $10 billion acquisition of Kate Pharmaceuticals, Ki

scr888 hacker app

锘?p>As a leading biopharmaceutical company in Hong Kong, Kingsray Biotech () is particularly concerned by investors in the recent period. In particular, after the US stock market Gilead's $10 billion acquisition of Kate Pharmaceuticals, Kingsray Biotech, a newcomer to the cancer immunotherapy (CAR-T), is facing a process of value revaluation. If the degree of attention is high, it will be accompanied by controversy. Looking back at my big A-shares, there is also the Chongqing beer ALLIN hepatitis B vaccine and the final loss of the game.

Compared with the hepatitis B vaccine, Kingsray Biotech's re-injection of CAR-T is fundamentally different, especially the current breakthroughs in research and development in this field, which seems to make people see a good dawn. As a star pharmaceutical company involved in the tens of billions of tracks, the aura of Kingsray Biotech is currently exciting for many investors.

But now that the concept is still in its infancy, let us return to the fundamentals and see how the quality of Kingsley Biotech is.

The company established the group in New Jersey, USA in 2002. The group has grown to be one of the leading suppliers of life science research and application services and products, and provides a complete range of services and product portfolios, with customers in more than 100 countries worldwide. . Dr. Zhang, Dr. Wang and Ms. Wang are co-founders of the Group's business. The company has established a large direct sales network covering more than 100 countries in North America, Europe, China, Asia Pacific (excluding China and Japan) and Japan. The company has established a highly diversified customer base, including pharmaceutical and biotechnology companies, colleges and universities, research institutions, government agencies (including government testing and diagnostic centers), and distributors. The Group provides a comprehensive and comprehensive service and product portfolio for global life science research and application services and product suppliers. According to the FrostSullivan report, the company ranked first in the global gene synthesis services market and third in the global DNA synthesis services market, accounting for % and % of the market share, respectively. The extensive and comprehensive life sciences research and application services and product portfolio consists of four divisions, namely (i) life science research services, (ii) life science research catalog products, (iii) preclinical drug development services, and (iv) industry Synthetic biological products. Services and products are used by scientists and researchers in basic life science research, transitional biomedical research, and initial medical development. Its synthetic bioproducts are also used by industry users of industrial enzymes, such as users in the food and feed industry. With strong sales and marketing team and strong research and development capabilities, the company maintains stable and sustained growth. In 2017, affiliated Nanjing Legend announced at the ASCO conference in the United States that CAR-T technology has made breakthroughs in the treatment of multiple, refractory myeloma. The company's life sciences research and development services segment consists of six main categories, each with different raw materials. For example, gene synthesis services use different types of restriction endonucleases; oligonucleotide synthesis services use nucleotide monomers; DNA sequencing services use BigDyeTerminator kits; production of protein service use media; and peptide synthesis services using amino acids; Antibody development services use experimental animals such as mice and rabbits. Global life sciences research services and product market grow steadily According to FrostSullivan data, global life sciences research services and product market size compound annual growth rate CAGR is %, China CAGR is %; expected to 2019, global life science research The service and product market will reach US$65.6 billion, China will reach US$5.4 billion, the 2015-2019 global market CAGR is %, and China CAGR is %. The company's life science research and development services revenue increased from US$48.57 million in 2012 to US$91.2 million in 2016. The compound annual growth rate CAGR of 2012-2016 was %, and its 2017H1 revenue was US$53 million, a year-on-year increase. The Group has launched a series of unprecedented new services in the new market 鈥?replacing existing services or addressing the current weak customer demand, further enhancing the Group's ability to integrate into the customer value chain. The Group continued to increase its investment in marketing activities, especially in online and offline channel development, including participating in more exhibitions and strengthening its relationship with customers. It is expected that the future revenue growth rate will remain at around 20%. The company's life science research catalogue product revenue increased from US$ 1.79 million in 2012 to US$ 5.3 million in 2016, CAGR of 2012-2016, and its 2017H1 revenue was US$ 3.5 million, a year-on-year increase. The group launched hundreds of second antibodies to make the company portfolio more diverse. The Group has significantly expanded the scale of magnetic bead products, reduced production costs, and further improved product batch consistency. It is expected that its future revenue growth will remain above 25%. Global DNA synthesis services are gradually upgrading the global DNA synthesis services market to a global market for molecular biology services. DNA synthesis mainly consists of two parts, namely oligonucleotide synthesis and gene synthesis.

DNA synthesis services are used in different life sciences to meet the needs of researchers and scientists.

As molecular biology tools prosper in life science research and expand the application of DNA synthesis services, the global DNA synthesis services market is expanding in the application of life science research.

With the use of advanced production equipment and the development of technology, DNA synthesis can provide stable DNA synthesis services at a lower cost in a shorter period of time.

According to FrostSullivan data, the global DNA synthesis services market has a CAGR of 8% in 2010-2014, of which CAGR of 7% for oligonucleotide synthesis and CAGR for gene synthesis are expected; by 2019, The global market for DNA synthesis services will reach US$100 million, and the global market CAGR of 2015-2019 is %, of which the CAGR of oligonucleotide synthesis is %, and the CAGR of gene synthesis is %.

According to 2014 earnings, the company ranked third in the global DNA synthesis services market with a market share of %.

In 2014, the global oligonucleotide synthesis services market segment had a CR5 of %, and the global gene synthesis services market segment had a CR5 of %.

The company is the world's largest provider of gene synthesis services, accounting for % of the global gene synthesis services market.

Global Genetic Analysis and Engineering Services Applications The global genetic analysis and engineering services market is one of the global market segments for the molecular biology services market.

Genetic engineering services are mainly divided into: (i) DNA sequencing services and (ii) other genetic engineering services, including various manipulations, modifications and analyses of DNA and RNA (except for synthetic synthesis and sequencing).

DNA sequencing is the process of determining the exact order of nucleotides within a DNA molecule.

Gene engineering (also known as genetic modification) is the use of biotechnology to directly manipulate the genome of an organism.

This is a set of techniques for altering the genome of a cell (including populations and gene transfer across populations) to produce improved or novel organisms such as the CRISPR/Cas9 system.

DNA sequencing and genetic engineering techniques can be used in a wide variety of applications, including analysis and modification of plant, animal and microbial genomes, as well as medicine and agriculture.

Human genome analysis is the main application area for disease research for DNA sequencing.

According to the FrostSullivan report, the increasing use of sequencing technology will be one of the factors driving the growth of the global genetic analysis and engineering services market.

In addition, with the introduction of new technologies, the price of sequencing services per million bases becomes more affordable.

In January 2014, the cost of sequencing human genomes dropped from $3 billion 20 years ago to $1,000. The cost of sequencing has fallen far faster than Moore's Law, so more energy in the sequencing industry will be placed on sequencing data in the future. Collection and analysis.

According to FrostSullivan data, in 2010-2014, the global gene analysis and engineering services market scale compound annual growth rate CAGR is %, of which DNA sequencing service CAGR is %, other genetic engineering services CAGR is %; expected by 2019, The global genetic analysis and engineering services market will reach 4.8 billion US dollars, and the 2015-2019 global market CAGR is %, of which DNA sequencing service CAGR is %, and other genetic engineering services CAGR is %.

The company focuses on oligonucleotide synthesis and gene synthesis. Genetic engineering services are not the company's strategic focus, so the company's market share in this segment is relatively small, estimated to be less than 1% in 2014.

According to the FrostSullivan report, the global genetic analysis and engineering services market is a relatively less concentrated market, with a CR5 of the global oligonucleotide synthesis market segment at % of 2014 revenue.

Global research protein and antibody related services and product status highlights research proteins and antibody related services and products mainly including the synthesis, expression, modification and purification of specific proteins and antibodies to facilitate related analysis and production.

Depending on the application method and the substance of the product, the services and products can be further divided into five categories, namely (i) peptide synthesis; (ii) recombinant protein production and expression; (iii) custom antibody services; (iv) single domain Antibody; (v) protein analysis services.

The growth potential of each of the relevant classifications is expected to lead to the development of global research protein and antibody related services and product markets.

According to the FrostSullivan report, the global market for research protein and antibody-related services and products is highly fragmented, mainly due to the relatively low demand for protein expression and proteomic analysis services compared to other life science services.

With the development of synthetic biology, its demand for global research protein and antibody-related services and product markets is expected to continue to grow.

According to FrostSullivan data, the global annual growth rate of research protein and antibody-related services and products in the market for 2010-2014 is CAGR of %; with the advancement of technology, the application of recombinant protein in clinical treatment is more popular.

It is estimated that by 2019, the global market for research protein and antibody related services and products will reach US$3.3 billion, and the 2015-2019 global market CAGR is %.

In 2014, the company's market share in the global research protein and antibody related services and products market was relatively small, estimated at less than 1%.

Global Life Sciences Research Reagents Market Highly Dispersed Life Science Research Reagents mainly include biochemical reagents, kits and enzyme tools developed and used by the Life Science Research Laboratory.

Biochemical reagents are directed to substances that undergo a chemical reaction, including various substances such as enzymes, substrate buffers, and other organic and inorganic compounds.

The kit includes a set of reagents and materials necessary for the development of one or more research experiments.

Enzyme tools include various types of enzymes involved in genetic engineering, such as DNA polymerases for PCR and restriction enzymes for cloning.

According to the FrostSullivan report, life sciences has become a priority for global government and privately funded research, with researchers and scientists purchasing more quality research reagents.

In addition, the price of research reagents and kits has declined due to market competition in recent years, and more research reagents and kits have been developed for almost all routine operations of life science research experiments.

The global life science research reagent market is highly fragmented and there are a large number of suppliers all over the world.

The relatively low technical barriers, combined with a wide range of life science research reagents, allow small suppliers to enter the market and survive.

Academic and government customers are highly price sensitive, further reducing market concentration.

According to FrostSullivan data, the global life science research reagent market size compound annual growth rate CAGR is % in 2010-2014.

It is estimated that by 2019, the global life science research reagent market will reach 21.8 billion US dollars, and the 2015-2019 global market CAGR is %.

In 2014, the company's market share of global life science research reagents was estimated to be less than 1%.

The global drug research and development service market will achieve a compound growth rate of 2015-2019. The drug development includes preclinical drug development and clinical drug development.

The preclinical drug development process consists of four main phases: target recognition, target validation, high-throughput screening, and lead compound optimization.

Preclinical drug development services are increasingly important for drug developers to validate identified therapeutic targets, identify new targets for targets, and gain insight into the biological mechanisms of disease and the interaction of drug candidates with targets.

Because the drug development process is complex, time consuming and expensive, many drug developers (mainly pharmaceutical and biotechnology companies) engage service providers to part of the drug development process to save time, money, and focus on Its core competencies, such as clinical drug development, manufacturing and marketing.

According to the FrostSullivan report, the Trusted Research Institute (CRO) provides drug development services to pharmaceutical, biotechnology and medical instrument industries and research institutions in the form of project-based research services that are primarily outsourced on a contract basis.

In addition, companies that specialize in drug development outsourcing services are considered pure CRO companies.

Main drug development service providers tend to acquire other service providers to strengthen their market position.

Since synthetic biology can explain disease mechanisms and target recognition, as well as provide useful tools for small molecule and antibody development, services can be provided with shorter turnaround times and higher efficiency, plus synthetic biotechnology expertise. Drug development service providers will have a competitive advantage.

According to FrostSullivan data, in 2010-2014, the global drug development service market size compound annual growth rate CAGR was %, of which pre-clinical drug development service CAGR was %, and clinical drug development service CAGR was also %.

It is estimated that by 2019, the global drug research and development service market will reach US$46.8 billion, and the 2015-2019 global market CAGR will be %. Among them, the preclinical drug development service CAGR is %, and the clinical drug development service CAGR is also %.

The global drug development services market is a moderately concentrated market, with CR5 being % based on 2014 revenue.

The entry barriers to the global drug discovery services market include hiring R\u0026D professionals, substantial capital investments, and strategic partnerships with drug developers.

The global market for industrial enzymes is hugely based on the high efficiency and wide application of enzymes for biofuels and bio-detergents, starch processing and winemaking.

Advances in synthetic biology have further increased the use of enzymes in multiple industrial processes and major R\u0026D activities.

The growth of inexpensive DNA synthesis and sequencing technologies, the emergence of protein design algorithms, and the ability to screen for numerous protein variants have led to rapid developments in the field of enzyme engineering.

According to the FrostSullivan data, the global industrial enzyme market size compound annual growth rate CAGR is % in 2010-2014.

It is estimated that by 2019, the global drug research and development service market will reach 6.7 billion US dollars, and the 2015-2019 global market CAGR is %.

The global industrial enzyme market is highly concentrated, with two market participants accounting for % of market share based on 2014 revenue.

The entry threshold includes the establishment of economic scale, existing major players and biotechnology expertise.

The global industrial enzyme market has low cost, high output, is more environmentally friendly, and has great market potential.

Diversified and Global Customer Base As of June 30, 2017, the company supplies 5000+ users in more than 100 countries worldwide, including pharmaceutical and biotechnology companies, colleges and universities, research institutions, government agencies and distributors. .

In recent years, the income of pharmaceutical and biotechnology companies has increased significantly, indicating that the company has a large increase in scientific research investment.

In terms of regions, North America (mainly the United States) and China's income have been greatly improved.

Strong sales and marketing team The company's success depends on its sales and marketing teams in the US and China. Nearly 90% of the company's sales and marketing teams in the US have obtained PhD or MS in life science related disciplines. .

The company has established an interactive online quotation and ordering system that allows for the selection of featured units and components from an online list to customize and order specifications for each order.

As of June 30, 2017, the company's online orders accounted for % of the total, and the number of offline orders was %.

Zhenjiang Expanded Production Capacity The investment agreement was signed on June 20, 2016. The company will invest two million investments and registered capital of 30 million US dollars.

Zhenjiang will be one of the company's important production bases in the future, and its research and development business will remain in Nanjing. In addition, it will transfer some life science research and development services.

This is equivalent to replicating the capacity of Nanjing, and the CRO business will increase nearly double the capacity.

The revenue of synthetic bio-products (industrial enzymes) from Synthetic Bio Rapid Growth increased from US$350,000 in 2014 to US$7 million in 2016, CAGR in 2014-2016, and 2017H1 revenue was US$4.7 million. increase%.

The Group has developed a range of new products, including glucose oxidase, fungal amylase, glucose isomerase, phytase and acid amylase, of which glucose oxidase has successfully entered the high-end baking market.

The company's indirect wholly-owned subsidiary, Nanjing Baisijie Biological Engineering Co., Ltd. (Basjie Nanjing) was appointed by the China National Standardization Administration Committee to draft a national standard for the enzyme industry, 'Guidelines for the Classification of Enzyme Preparations'.

During the 2017H1 reporting period, the Group has a newly registered patent in China and three patent applications for glucoamylase production technology are pending.

After the company's production capacity has been in place in recent years, the gross profit rate of industrial enzymes will increase significantly. We expect the compound annual growth rate of the sector to remain at around 60% in the next few years.

The development of cell therapy has an overtaking trend. CAR-T treatment represents the most advanced tumor immune cell therapy technology.

This is a cell therapy technology, scientific name 'CAR-T'.

The CAR-T treatment represents today's most advanced tumor immunocytotherapy technology by removing T cells from the patient and genetically modifying the cells to program the effects of tumor cells expressing specific proteins. T cells, which confer T cells the ability to recognize specific tumor cells, specifically kill the tumor cells, and then inject them into the patient to attack the cancer cells.

The United States local time June 5th, the world's largest, the highest specification and level of oncology academic conference - 2017 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, the company's wholly-owned subsidiary Nanjing Legend Biotechnology Co., Ltd. The medical results announced by Dr. Fan Xiaohu, the company's chief scientific officer, have caused great shock in the industry. The cell therapy technology independently developed for multiple myeloma can make the objective response rate of the disease reach 100%.

Nanjing Legend Biotechnology Co., Ltd. has been developing CAR-T technology and products since the end of 2014. At present, it has developed a series of precision treatment products with independent intellectual property rights.

The CAR-T technology product LCAR-B38M based on the BCMA target is effective in treating multiple myeloma.

As of September 18, 2017, the company's wholly-owned subsidiary Nanjing Legend has cooperated with four Chinese top three hospitals in clinical research and applied its own CAR-T technology, and has treated 71 patients with relapsed and refractory multiple myeloma. Patient.

40 patients who underwent treatment were followed up for a minimum of 3 months, of which 24 patients achieved complete response, 12 achieved excellent partial response, 3 achieved partial response, and 1 did not report response due to The relevant patient withdrew from the clinical study.

Of all patients treated, 66 patients experienced varying degrees of cytokine release syndrome.

In the first half of 2017, the company's operating income was US$100 million, a year-on-year increase, and the compound annual growth rate CAGR of 2014-2016 was %.

In terms of sub-sectors, life science research services revenue was 53 million US dollars, year-on-year; life science research catalogue products revenue was 3.5 million US dollars, year-on-year; pre-clinical drug research and development service income was 2.2 million US dollars, year-on-year; industrial synthesis Bioproducts revenue was $4.7 million, a year-on-year increase. In the first half of the year, the gross profit of the company was US$100 million, a year-on-year increase. The compound annual growth rate CAGR of 2014-2016 was %; the gross profit margin increased from 63% in 2014 to the current %. In terms of company R\u0026D expenses, in the first half of 2017, the company's research and development expenses were US$4.8 million, a year-on-year increase. This is mainly used for the continuous development of LGCAR-T, next-generation technology and new service development and product performance, and new research and development projects under the Industrial Synthetic Bioproducts Division. Remind you of the address of this article:


Copyright Notice:Original article of this site, in2018/07/20 scr888 hacker app,由 Publish。

Please indicate:scr888 hacker app:http://en.hengzhongyuanlin.com/Party/scr888_hacker_app/

scr888 hacker app leading biopharmaceu company

More